| Biotech Roundup: GSK’s Ante, Shakeup at Sage, Telehealth’s Rise & More | Frank Vinluan | 04/10/20 | National |
| Bio Roundup: Pandemic Declared, Rubius Restarts, Kymera’s Cash & More | Frank Vinluan | 03/13/20 | National |
| Acceleron Drops Drug for Rare Muscle Disease After Mixed Phase 2 Data | Frank Vinluan | 03/10/20 | Boston |
| Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More | Frank Vinluan | 01/31/20 | National |
| Third Time’s the Charm as Acceleron Drug Shows Early Promise in PAH | Frank Vinluan | 01/28/20 | Boston |
| Bio Roundup: FDA Approvals, Intrexon’s Shift, Melinta Bankruptcy & More | Frank Vinluan | 01/03/20 | National |
| Biotech Roundup: Gottlieb v. Juul, Solid Slumps, Avidity Gets $100M & More | Sarah de Crescenzo | 11/15/19 | National |
| Anemia Drug From Acceleron Pharma and Celgene Wins FDA Approval | Frank Vinluan | 11/08/19 | New York |
| Celgene Files for FDA Approval of Blood Disease Drug | Frank Vinluan | 04/05/19 | New York |
| The Life, Troubles, and Celgene Legacy of Deal Guru George Golumbeski | Ben Fidler | 03/11/19 | National |
| Bio Roundup: An Alzheimer’s Head-Scratcher, OUTBio, GSK & Gilead Shakeups | Ben Fidler | 07/27/18 | National |
| Bio Roundup: Pfizer’s Prices, Novartis Cuts, Gene Therapy Guide & More | Frank Vinluan | 07/13/18 | National |
| Acceleron, Celgene Drug Shines in Phase 3 Test in Rare Blood Disorder | Frank Vinluan | 07/09/18 | Boston |
| 15 For ’18: Key Clinical Data to Watch For Next Year (Part 1) | Ben Fidler | 12/04/17 | National |
| With FDA Nod, Agios, Celgene Get Speedy OK For Blood Cancer Drug | Ben Fidler | 08/01/17 | Boston |
| Bio Roundup: Trumpcare Is Mean, SCOTUS Says Go, Merck’s Myeloma No | Ben Fidler | 06/16/17 | National |
| ASH Roundup: CAR-T Shuffle, Hemophilia Updates, Checkpoint Progress & More | Ben Fidler | 12/06/16 | National |
| Ex-Celgene Dealmaker Tom Daniel Charts a New Course Advising Biotechs | Ben Fidler | 10/17/16 | New York |
| East Coast Bio Roundup: NY Startups, Editas, Bonney, C4 & (Much) More | Ben Fidler | 01/08/16 | Boston |
| Verastem Sinks as Mesothelioma Study Halted For Futility | Ben Fidler | 09/28/15 | Boston |
| East Coast Biotech Roundup: Bluebird, Sarepta, Synlogic & More | Ben Fidler | 05/22/15 | Boston |
| East Coast Biotech Roundup: Celgene, Blueprint(s), Intarcia & More | Ben Fidler | 05/01/15 | Boston |
| Celgene, Versant Shake Again, Cut $30M Deal For Toronto Biotech | Alex Lash | 04/29/15 | New York |
| East Coast Biotech Roundup: Cellectis, Bristol, What’s Hot & More | Ben Fidler | 04/13/15 | Boston |
| Flagship Ventures Raises Sails for $537M Fund, Its Largest to Date | Alex Lash | 03/26/15 | Boston |
| Investors Line up For Westphal as Muscle Cramp Startup Upsizes IPO | Ben Fidler | 01/28/15 | Boston |
| ASH Roundup: Immunotherapy Stars, Gene Therapy Leaps Ahead | Ben Fidler | 12/11/14 | San Francisco |
| Polaris Partners Adds $450M for Seventh Fund | Curt Woodward | 11/24/14 | Boston |
| To Fight Cramps, Christoph Westphal Taps Boston All-Stars for $40M | Ben Fidler | 09/09/14 | Boston |
| East Coast Biotech Roundup: Acceleron, Seres, Sage, & More | Ben Fidler | 07/18/14 | Boston |
